tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Cue Biopharma (CUE) and Siemens Healthineers AG (OtherSEMHF)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cue Biopharma (CUEResearch Report) and Siemens Healthineers AG (SEMHFResearch Report) with bullish sentiments.

Cue Biopharma (CUE)

In a report released today, Michael King from H.C. Wainwright maintained a Buy rating on Cue Biopharma, with a price target of $20.00. The company’s shares closed last Wednesday at $10.60.

According to TipRanks.com, King is a 4-star analyst with an average return of 12.6% and a 43.1% success rate. King covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Werewolf Therapeutics, and Intellia Therapeutics.

Cue Biopharma has an analyst consensus of Strong Buy, with a price target consensus of $27.60, a 177.7% upside from current levels. In a report released today, Berenberg Bank also maintained a Buy rating on the stock with a $30.00 price target.

See the top stocks recommended by analysts >>

Siemens Healthineers AG (SEMHF)

Berenberg Bank analyst Odysseas Manesiotis maintained a Buy rating on Siemens Healthineers AG yesterday and set a price target of EUR75.00. The company’s shares closed last Wednesday at $65.60.

According to TipRanks.com, Manesiotis is ranked #6720 out of 7757 analysts.

Currently, the analyst consensus on Siemens Healthineers AG is a Moderate Buy with an average price target of $78.47, implying a 19.6% upside from current levels. In a report issued on January 19, Jefferies also upgraded the stock to Buy with a EUR75.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CUE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed